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Abstract- The present article attempts to summarise the elements of the
mechanism of action of the antitumor drug ci___s-Pl ati n presented the Iast few
years. Highlights on the discovery of the drug and the development of it’s
second generation derivatives are presented, as well as the ways that
cis___-DDP reacts with biomolecules as DNA and proteins and their models e.g.
nucleosides, nucleotides. Also the hydrolysis data are presented for
ci__s-DDP and its’ inactive congener trans-DDP, as well as for the second
generation drug carboplatin. Finally, useful l conclusions are given from
this work, pointing out the unanswered questions about the action of cis-
DDP as well as its differences in action, in comparison with trans-DDP.
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(a) Introduction The compound dichloro-diamine-platinum (II), of the
Cl was known since 1844 in two forms, the empirical formula Pt(NH3) 2 a-Pt(NH3)2C1 2
or Peyrone salt2(ci__s-platin) and the 6-Pt(NH3)212 or Reiset
salt (trans-platln). The pioneering work of Werner [I] 6n the structure
and bonding of coordination compounds, led to the assignment of a square
planar geometry for these complexes (Fig. I).
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(a) ci__#s-platin or cis-DDP and (b)
of trans-effect was made by the Russsian chemist Chernyaev [5].
subsequently studied in depth by Basolo [6], Dra9o [7], Sadler [8]
of trans-p at n
ructure of both isomers was elucidated by X-ray diffraction
2].
um (II) is classsified as a "soft" Lewis acid, according to
3] or class b, and generally forms more stable bonds with donor
racterized also as "soft" Lewis bas#s (e.g. N,S,P etc), while with
ses (e.g. Cl, H20, NO CO SO etc) it forms weaker bonds.
s on ligand substitut3
3 4
Ion reactions in square planar complexes led
velopment of the kinetic trans-effect by Chatt [4]. The discovery
It was
etc and
it continues to be studied even today.
Around 1965 the first publication appeared by B. Rosenber9 and his
collaborators [9] describing the unusual behavior of E.coli bacteria
culture, in the presence of platinum electrodes. This was a part of a
biophysical study of the growth of bacteria under the influence of the
electric current. The bacteria were forming long filaments, about 300
times longer than the normal size [9]. This filamentous growth meant
inhibition of cell division, but not of cell growth. The platinum
electrodes were selected because of the inertness of the metal, while the
observed filamentous growth was starting I-2 hrs after the passage of the
electric current. It was subsequently found that for this abnormal growth
of the bacteria, small amounts of metal in the form of the complex
(NH4)2PtCI_ (I-10 ppm) were necessary. The same behavior was also observed
in the
4 presence of similar amounts (about 8
transition metals as well, like Rh, Ir, Ru,
effect observed with Rh complexes, e.g. RhCl
Later it was
el ect rode formed
NH4CI, used
growing, was transformed into cis-Pt(NH
ppm) of complexes of other
etc, with a more pronounced
or (NH )2RhCl_ [10],
found by Rosenber9 eta_.
3 [10,1] tha the platinum
electrolytically [PtCl 6] which after reaction with
as a nutrient in the medium in which E.coli bacteria were
3 )2C14"
This in turn after UV
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rrad at on was produc ng among others c s-Pt (NH3) 2
C 12"
Both
cis-(NH___3_)2PtCl and cis-(NH )PtCl were the active species for the
4the
3 2 p o uc  on , so
trans-Pt(NH ) Cl analog was inactive.
Based on3tge 2above properties of the two cis-complexes of Pt
2+
and Pt
4+
and knowing since 1931 that ruthenium compounds and RhCl were inhibiting
the growth of adenocarcinoma and of mice sarcoma, Rosenbe9 [12] decided to
test them against sarcoma-180 and mice lymphocytic leukemia 1210 and
obtained the first satisfactory results. In 1973 Rosenberg [13] presented
the results of clinical trials (phase I and phase II) for cis-(NH3)- 2PtCl 2
(ci___s-platin, or cis-DDP) started in 1972, as well as in vitro tesls of
various platinum complexes against a broad spectrum of tumors. Thus, from
a broad spectrum of 28 tumor types with 50 to I00% cures (phase I clinical
trials), 7 types of toxicity effects were discovered, with as more serious
ones, nephrotoxicity, nausea and vomiting. Nephrotoxicity was determining
the limiting dose of the drug. The best results of cis-DDP were found
against testicular and ovarian cancers. The problem of nephrotoxicity on
the other hand, was solved by the idea of Cvitkovic and Krakoff at the
Sloan Ketterin9 Institute, to use extensive hydration and mannitol prior to
drug administration. Cis-DDP was subsequently used in combinational
therapy with vinblastine and bleomycine against testicular cancer with >95;
cures.
Analogs of cis-DDP exhibitini antitumor activity were also presented by
Rosenber9 in 1978 [14] (Fig. 2).
R X
R NH- NH- MeNH
2 2
EtNH i-PrNH 2
R X 2 2-2
X CI-, Br-, -OOC-COO- NI-L
Fig. 2. Analogs of cis-DDP with antitumor activity.
Finally, in 1978 the complex compound cis-(NH_)2PtCl 2
(Peyrone’s Salt)
was approved for clinical use as a drug under te name "Platinol" by the
F.D.A. (Food and Drug Administration) of the USA, and under the name
"Neoplatin" in Great Britain in 1979 by the DHSS (Department of Health
System and Security).
Since 1983 the drug comes first in sales in the USA and worldwide among
all the analogous anticancer drugs. Today only the derivative of ci__s-DDP,
cis-[ (NH)oPt(CBDCA) ], or ci__s-diamino-[ I, 1-cyclobutane-dicarboxylate-
(2)-0,0’ latinum (II), named Paraplatin or Carboplatin, or JM-8 is
commercialy widely used (Fig. 3). Figure 3 presents a few analogs of
ci__s-DDP with satisfactory antitumor activity that are presently under
clinical trials in various phases, except carboplatin, which is already in
use. Carboplatin is used today in combination with other antitumor drugs
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[15] or with radiotherapy against testicular, ovarian, head and neck
cancers. It has however little effect against cancers with a great
percentage of mortality, like lung cancer and cancers of the
gastrointestinal tract [16].
Today a great deal of research work is still carried out around cis-
and trans-DDP and their derivatives. In particular about 2000 relevant
publications were referred, during the years 1981-1992 in the Chemical
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Fig. 3. Some newer antitumor complexes of Pt(II) and Pt(IV);
(i) Carboplatin or Paraplatin or JM-8 or CBDCA or ci___s-diamino-[O,O’-1,1-cyclo-butanm-dicarbo-
xylato] platinum (II), (ii) Zeniplatin or CL 286, 588 or [N,N’-2,2-bis(aminomethyl)-l,3-pro-
panodiole] [O,O’-l.l-cyclobutane-di-carboxylato] platinum (II), (iii) Oxaliplatin (Oxalato-
platinum) or..cis-(N,N-1,2-diaminocyclohexane)-(tans-l)-oxalato-platinum (II), {i_yv) DAGH-Pt
or ci__s-(N,N-1,2-diaminocyclohexane)-(trans-l)-dichloro-pl&tinum (II), (X) CHIP or Iproplatin
or cis-(bis-isopropylamins)-(tanF-I)-dihydroxy-cis-dichloro-platinum (IV),(v_ii) Enlopl&tin or
CL 287,110 or [0,0’- 1,1-cyclo-butane-dicarboxylato] [N,N-tetrahydro-4H-pyrane-4,4-dimethana-
mine] platinum (II), (vii) Tstraplatin (Ormaplatin) or NBC 363812 or Tetrachloro-[N,N-(d,1-
trans)-l,2-diaminocyclohexane] platinum (II) and (vii____ii) Bpiro-platin or TNO-6 or [N,N-(1,1-
bis-aminomethyl)-cyclohexane] (Sulfato)(hydrato)platinum (II).
Abstracts [17]. In 1984 Rosenberg was honored with the Charles F.
Ketterin9 award, sponsored by General Motors, where he presented a review
of his work [18].The present paper is attempting to briefly review what is
known today on the mechanism of action of cis-DDP and carboplatin, which
almost replaced the former and is the only one in use.
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(b) Structure-Activity Relationship The aquired knowledge on the activity
and chemistry of cis-DDP and its inactive congener trans-DDP, even from the
early studies and the testing of many analogs of the drug against various
tumors, provided the first elements of structure-activity relationship of
these complexes [19-2], summarized in the folllowin9 rules:
(i) T
compounds should be neutl and correspond to formulae
cis-Pt (am) X or cis,cis,trans-Pt--(am).X^Y^, with am:amine and
9ands (9ood leav-9 groups), z(i The ligands X, should
consist from groups or donor atoms that make bonds with Pt(II) of
intermediate strength. For this or other reasons (e.9_ activation 2by
enzymes) these are 9ood leavino roups Examples are SO. -, Cl-, C^O. -,
citrates [(OOCCH ) C(OH)(CHCO0)_] or other dicarboxylates. For the
compounds of Pt(V, the igands Y are mainly OH- occupying the axial trans
positions. (iii) The amine li9ands should have at least one N-H group
whether they are mono or bidentate so that they will be able to form at
least one hydrogen bond. All the compounds with nitrogen donor l i9ands
containing no hydro9ens capable to form hydrogen bonds, do not possess
antitumor activity, though they can also bind with DNA.
The possible roles of the N-H group in the biological activity of the
compounds, may either be kinetic (e.9. a possible relationship with the
approaching of the macromolecule of DNA) or thermodynamic (e.9. with the
additional (de)stabilization after binding with the biological target of
DNA) or steric (e.9. hindered rotation, due to the increase of bulkiness of
of the nitrogen donor l igand) or reasons related to the transport of the
drug within the cell. In any case, it is even today a subject of extensive
research [2].
It should be emphasized that the above rules are not universal and that
some Pt(II) compounds with increased cytotoxicity or even antitumor
activity do not obey them [28]. A few examples are liven below:
(i) Complexes with two diamine units bridged with a carbonate bridge of
NH )}] [29-31] with maximum formula [{cis-Pt(NH3)2Cl2}2{l-N N-(NH2(CH2) n 2
activity when n=5.
(ii) Dimeric or trimeric hydroxo-bridged complexes of Pt (II) of formulae,
where[Ci--s- Pt(NH^CH(CH3)2)DACH=, 2-diam nocyc2-
(-OH) ]2 (NO-)3l ohexane ].and
[cis-Pt(R, R-DACH) (g-OH) ]
3 (NO3) 3
(ii__i) Complexes of formula [Pt(diam)(RR’SO)C1](N03), with diam=a bidentate
amine and RR’SO=a sulfoxide [33].
(i_yv) Increased cytotoxicity was observed in complexes of type
trans-[PtC12(RR’SO)(quin)] and trans-[PtL2C12], here, quin=quinoline and
L=pyridine, N-methyl-imidazole, thiazole, qulnoline [34-+36].
(v) Compounds of formula ci--s-[Pt(NH3)2(N-Het)Cl ] with N-Het=a
heterocyclic amine [37, 38] containing only one }avin9 group.
(vi) Antitumor compounds of formulae, [Pt (N N-NRCH CH NR)L2] and
[-(N,N-NRCH2CH2N )(py)2], R=R’=polyphenyl, L=pyridine or methyl pyridine
[39].
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(vii) The trans-[PtCl {E,E-HN=C(OR’)R} ] possesses a remarkable antitumor
activity, larger than2its cis-EE and c2s-ZZ isomers [40, 41].
In conclusion, complexes with antitumor properties include cationic,
compounds containing four nitrogen donor atoms around platinum, nitrogen
donor ligands without hydrogens
trans geometry.
(C) Binding sites of cis-DDP
toxicities From the beginning
the way that cis-DDP exhibits
molecule and the binding sites
was of great importance for the
with reduced toxi
It was soon fo
tumor cells in vi
(i) the productio
of lysogenicity,
(v) the inactivat
DNA.
for hydrogen bonds, and complexes with
responsible for cytotoxicity and side
it was obvious that the understanding of
its antitumor action, i.e. the target
in the cell causing the antitumor action,
development of new more effective analogs
city.
und that DNA was the target molecule of ci__s-DDP within the
vo, because the drug had the following biological effects-
n of a filamentous growth in bacteria, (i_i) the production
(iii) carcinogenicity, (iv) inactivation of viruses and
ion of bacteriophage viruses that contain and transport
Cis-DDP had also the following biochemical effects supporting the above
conclusion- (i) selective inhibition of the synthesis of DNA and not of RNA
or proteins, (ii) inactivation of the substrate of the enzyme
DNA-polymerase, (iii) selective binding with DNA, (i_v) other analogous
complexes are bound in a similar manner to cis-DDP with DNA and finally,
(v) the relationship between the antitumor activity and inhibition of the
growth of bacteria [42].
The fact that the nuclear DNA was the primary target of cis-DDP within
the cell, led to extensive research of the study of the interaction of the
drug and other platinum salts with DNA and its constituents in vitro with
the aim to discover the binding sites of the metal, its general reactivity
and the possible modifications of DNA caused by the binding, leading to
death of the cell. In 1971, the first publication on the interaction of
cis-DDP with DNA, studied with UV and CD spectroscopies appeared [43]. The
hypochromicity shown in the UV spectra of the double helix of DNA,
indicates perturbation on the structure of the macromolecule upon platinum
binding, i.e., the disappearance of the stacking interactions between the
bases (increase of ). This was interpreted as rather due to a covalent
bonding of Pt(II) with the bases of DNA. At almost the same time the
ir spectrum of the complex ci__s-Pt(ado)Cl
(ado=adenosine) was studied in
the solid state, with Pt(II) bound at t.: 7 atom of the base [44].
Various techniques were employed in subsequent studies of interaction of
platinum salts with nucleosides and nucleotides (DNA constituents), leading
to the conclusions that the metal could mainly bind at the N7 and NI sites
of purines and the N3 site of pyrimidines [45-53]. Later similar studies
of nucleobases showed additional binding sites the N3 and 06 of purines and
the exocyclic amino group (-NH) of pyrimidines [54, 55] (Fig. 4).
(d) Hydrolysis of cis- and t2rans-DDP in aqueous solutions In aqueous
solutions the two isomers, cis- and trans_-(NH3) PtCl
are hydrolyzed as
shown in Fig.5 and Fig.6 [56-61]. The concentrat2on the various species
formed depe in each case on the pH and the ionic strength of the
I-5
solution. Pt and N-NMR [60, 62, 63] have been used in many cases to
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identify the species formed, while many hydroxo-complexes were isolated in
the solid state and their structure was solved by X-ray diffraction [17,
64-66].
Fig. 4.
Fig. 5.
i,,, i
\ \ \
Structures and bondin9 sites of (a) 9-Alkyl-Guanine, (b) 1-Alkyl-
Cytosine, (c) 9-Alkyl-denne, (d) 1-Alky]-Uracl and 1-Alky]-
Thymine.
IN
Hydrolysis of cis-DDP in aqueous solution.
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Fig. 6. Hydrolysis of trans-DDP in aqueous solution.
From Figs. 5 and 6, it is seen that the concentrations of the
monohydro-monochloro-diamine complexes in aqueous solutions, with
strength 1=0.1 and temperature 25, are 88 for the cis- and 54 for
trans-analo9, calculated as percentages of the starting compounds.
The lower activity of trans-DDP compared to cis-DDP may be explained
the smaller value of pka of the former (5.63 compared to 6.85 for
cis-analog), for the equilibrium, + +
(NH )2Pt(H^O)Cl] [(NH3)2Pt(OH)C1] + H
Z As a result under physiological conditions and since the OH group
active
ionic
the
by
the
The
within
take pl
atoms o
than Pt
place t
Its
is
not a 9ood leaving group as compared to H O, the concentration of the
trans-mono-hydro-complex available is considSrably reduced, consequently,
its reaction with DNA is also reduced [56].
blood plasma has pH=7.4 with chloride concentration of 100mM, while
the cell it is only 4 mM. Consequently, the hydrolysis reactions
ace in the cell plasma, by the hydrated species with the proper
f the biomolecules. It is noted that Pt(II) is hydrolyzed faster
(IV) and that the l igand substitution reactions in the former take
hrough a pentacoordinated intermediate [57].
hould also be noted that the species distribution of Figs. 5,6 is
not strictly followed in vivo, since it is possible for the complexes to
react with the various biomolecules, e.g. proteins of blood serum, in
sulfur containing sites (glutathione, methionine etc) [67-70], prior to
reaching thermodynamic equilibrium.
The hydroxo bridged species, that may also be formed in regions with
high platinum concentration [71], are inert and believed to be related to
the neurotoxicity of the drug. The release of ammonia from cis-DDP when
the drug reacts with sulfur donors, like methionine [72], rises the
question whether this release contributes to its cytotoxicity [72, 73].
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2. BINDING MODES OF METAL IONS WITH DNA
(a) Introduction (_Description of DNA structures) The secondary structure
of the B-form of DNA is shown in Fig. 7. Part of its primary structure
with the possible sites on the bases for coordination with platinum is also
given in Fig. 8.
,3Q
(a)
H
N--H O
N N H-N
N N H O H
ADENINE THYMINE
H
O
,N N H- N
N N N-H O H
H
GUANINE CYTOSINE
Fig. 7. (a) Structure of B-DNA ( Reproduced by permission from ref.[74] )
and (b) hydrogen bonds between base pairs, according to Watson-
Crick.
Useful parameters of the DNA structure [74] are,
(i) Translation per" residue- The distance in the DNA axis, between two
successive base pairs (in B-DNA it is 340 pm, or 3.4 ).
(.ii) Base pairs per turn- It is a measure of the magnitude of the helix
and represents the total number of bases after a complete turn of the
helix, i.e. after arriving again to the origin where it was started
from (For B-DNA we have 10 pairs per turn, i.e., per 10 X 340 = 3400 pm).
(iii) Helical pitch Distance run from the origin of the helix, required
for a complete turn (in B-DNA is 3400 pm or 34 ).
(iv) Base tilt Angle of the plane of base pair with the perpendicular to
00 the axis of the helix plane at the same point (In B-DNA it is i.e.,
every base pair determines a plane perpendicular to the helix axis or
otherwise the planes determined by the bases are perpendicular to the
axis).
(v) Base displacement Distance of the centre of the base pairs from the
helix axis (0 pm in B-DNA).
The B-form is the most common in solution. There are also the right
hand side A-helix, that has a total number of 11 base pairs per turn, base
tilt of 20 and the left hand side, Z-form (zig-zag tpe), which is more
scarce. On a B-helix, the axis of every base pair (i.e., the straight line
connectin the centre of the bases) is turned in relation to the previous
pair by 36 (e.9. the angle of the two axes is 36). In this way a major
groove and a minor groove are finally formed in the macromolecule. The
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first (major groove) is 24 A wide and it is considered as the primary
rec_ognition site of the proteins, while the second (minor groove) is onl
10 wide with smaller depth and interacting onlM with small proteins, In
the B-helix the minimum distance for two bases belonging to two different
helixes is 7 [75],
(b) Formation of a DNA-intercalator "complex" Intercalators are planar
molecules, mainl organic polyaromatic systems, havin the abilit to
intercalate between two successive base pairs kept near, b9 stacking
interactions. A DNA-intercalator "complex" is thus formed. This possiblit
of course exists on Iw for a ds DNA and not for ss DNA. The effect of inter-
calation in the geometr of the molecule is the lengthening of the helix
[70], so that the distance between the base pais in the two sites of the
intercalato is increased to 7-8 from 3,4 initially, resultin to
biochemical chanes, e.g. inhibition of enzymes like RNA polmerase and/or
topoisomerase II [75].
Several structures of such complexes were solved with X-ra diffraction
[77,78]. Proper experimental methods for the detection of this tgpe of
interaction, were developed based on changes of the structure of the macro- +
molecule [79-81]. The structure of the complex [(trp)Pt($CH2OH2OH)]
(trpy-tripyridyl) with the dinucleotide dCpG (Fig. 9), which opens +up the
double helix of B-DNA b 23 [82] or the structure of [(trpy)PtCl] with
AMP [78] are among the most characteristic ones.
ADENINE
Fig. The structure of the tetranucleotide model of a part of single
helix (primar structure) of B-DNA, d(TpGpCpA), where the bonding
sites with platinum are indicated.
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Fig. 9. (a)
(b)
d(CpG)
:5’ C2" endo
CY endo
C2’ endo
CH CH OH 3" 2 2 b
(a) [--c
C3’ endo
) +
Structure of the complex [(trpy)Pt(S-CH2CH OH)] and
structure of its interca]ator comp]ex w]th2the dinuc]eotide
( Reproduced by permission from ref.[82] ).
+ Others include the complex [(trpy)PtC]] which reacts with regions rich
in G-C of ds DNA and is used for se]ective protein ]abe]ing, since it has a
9rear affinity for cysteine, much sma]ler for histidine and not at a]] for
methionine [83], a]so of the "comp]ex" [(en)Pt(bpy)]2+ (en-ethy]enediamine,
bpy=bipyridy]) with ANP [84,85]. The interaction between these two
mo]ecu]es in so]ution was a]so studied by CD and H NNR [86]. The ang]e of
unwinding of DNA in these comp]exes was found to be 6-19, depending a]so
on the presence of a coordination binding [87].
Fina]]y, the so ca]]ed "bis-interca]ators" sou]d a]so be mentioned.
For examp]e, in the comp]ex [{(trpy)}Pt}2(can)] (can-canavarine) (Fi9
10), the aminoacid (canavarine) bridges two Pt(I) atoms as a "bis
interca]ator", most probab]y through the minor groove of DNA [88]. Severe]
ana]ogs to these comp]exes with peptide bridges were a]so synthesized, in
searching for compounds with se]ective binding with DNA 89].
A]so, comp]exes of the type A, A- [N(phen)
3 (o-phen= 1,10-
phenanthro]ine, n-2,3, N=Zn, Ru, Cu, Co, etc) may react_simi]ar]y. With
meta]s with more than one stab]e oxidation states ]ike Co3+, free radica]s
may be produced near their binding region with DNA, resu]tn9 to oxidative
breaking of the macromo]ecu]e [42].
(c) Externa] sphere comp]ex formation (onic binding) The counter ions of
the negative charges of the phosphate groups in ds DNA that partia]]y +
neutra]ize its charge are usua]ly Na or other sma]] mete] cations. They
may of course be the positive parts of other biomo]ecu]es, ]ike proteins.
For examp]e Au(TT), in the form of AuC] at ]ow concentrations is bound
to the phosphate oxygens, while at igher ncentrations wit+
the
nucleobases [42]. Also, the complex [Co(NH3) 6] or the Mg(H_O)
6__ are
known to stabilize the Z-form of DNA through a B->Z transition [90].
Greater stabilization is achieved with the first complex, because (a) it
has a larger charge, (b) it contains igands forming hydrogen bonds and (c)
igands that are not readily exchanged with solvent molecules.
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It should also be noted that the complex [Co(NH ) ]
today as a reagent for the B Z transformation of INX
than the previously used methods for this purpose, +
concentration (2.5 M Na ) or ethanol (60%) etc.
Concerning the binding of platinum salts with DNA
molecular mechanics calculations showed that cis-DDP may
directly or through water molecules with the phosphate
macromolecule [91,92].
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3+
is widely used
with better results
i.e., high salt
in this manner,
interact either
groups of the
(d) Internal sphere complex formation (Covalent bindin).. Many metal
are covalently bound with the bases of DNA. Extensive reviews on
subject exist [49, 51, 53], tosether with X-ray crystal
and formation constants determinations in solution [94].
for conclusions).
structures [50,
(See Sect on
Fig. t0. Molecular structure of the intercalator compound {[Pt(trp)]
2 ( Reproduced by permission from ref.[88] ).
3. BINDIN( OF cis- AND trans-DDP WITH DNA AND/OR PROTEINS.
ions
the
93]
lc,
3+ Can}
(a) Introduction Both cis- and
donor atoms of the DNA bases, [26,
of cis-DDP are given in Fig. 11.
More particularly, cis-DDP can bind with
ways (Fig. 11).
(i) Monodentate binding w
(ii) Formation of "inte
belonging to different st
trans-DDP form covalent bonds with the
95-97]. The various ways of DNA binding
DNA in one of the following
ith only one base of DNA.
rstrand crosslinks" (InterSCL)
rends of DNA
(ii___i) Formation of "intrastrand crosslinks" (Intra$CL)
similar or not, bases of the same strand of DNA
(i_v) Formation of DNA-Pt-protein crosslinks, and
(v) Bidentate binding with onl one DNA base.
with two bases
with two successive,
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Fig. 11.
1.2 1.3 1.3 1.4
cisplatin (b) transplatin
Various ways of (_a_a) DNA binding of cis-DDP or/and proteins and
(b) differences in the conformation of the macromolecule from the
formation of 1,2- or" 1,3-TntraSCL by cis-DDP and 1,3- or 1,4-
IntraSCL by tr’ans-DDP.
The percentage formation of each type of bonding were quantitatively
calculated [98,99,100]. Thus the percentage of the intrastrand crosslink
betweeen two successive bases of guanine of the same strand of DNA
(1,2-IntraSCL) formed by cis-DDP on the d(GpG) part of the macromolecule,
varies from 50-60%, whereas IntraSCL between successive guanine and adenine
bases (d(ApG)type) by 20-30 percentage. About 10% of cis-DDP forms
1,3-InstraSOL with two guanine bases separated by a third base of the type
d(GpXpG). More scarce are the InterSCL between guanine bases belonging to
different strands of DNA (<I;) and the DNA-protein crosslinks (<1%). More
types of binding are also taking place in small percentages, but they have
not yet been identified [98,99].
(b) Intrastand Crosslinks (IntraSCL)..- The reactions of ci__s- and trans-DDP
with DNA proceed in various steps, where kinetic factors play an important
role. The rate determining step of the monodentate binding of the two
isomers with DNA, is the substitution of a chloride by a water molecule,
with half life t -1.9 hrs for trans- and 2 hrs for cis-DDP [101]. The I/2 monohydrated species produced, react fast mainly with the N7 of guanine of
DNA, which is not only nucleophilic but also easy to be reached by the
salt, in the direction of the major groove in B-DNA. In a first stage,
electrostatic interactions between the negatively charged sites of the
macromolecule (e.. phosphates) and the cationic monohydrated species
[(NH )_Pt(H_O)Cl] seem to be important. According to our knowledge,
ci preers mainly parts of DNA containing two successive guanine
bases, e.9. of the d(GpG) type, but not all of them are equally possible
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rate
the
for attack [I02]. The hydrolysis of the second chloride is again the
determining step, t/-2.1 hrs for the cis- and tl/2 3.1 hrs for
trans-isomer, at pH=Z. [101].
Experimental evidence for the formation of intraSCL in DNA between two
N7 atoms of neighboring G molecules, also referred as a 1,2-1ntraSCL, are
provided by the following series of experiments:
(_i) A large increase is observed in the value of the flotation density for
the polynucleotide, poly(dG)poly(dC) that was treated with cis-DDP,
compared to the corresponding increase of the platinated poly(dG.dG) and
the platinated monomers.
Both poly(dG.dC) and poly(dG).poly(dC) are synthetic polymers with known
Poly(dG.dC) contains G:C=I:I
helix structure with the
M.W
57% dC.
sugar
in a strict sequence and it
guanine bases taking the
homopolymer of double helix
The first helix is poly(dG)
in the former adopting a
base sequences.
has a double
ant i-conformat on.
The poly(d).poly(dC) is a high
structure and it contains 43 dG and
and the other poly(dC), with the
syn-conformation [03].
The fact that only poly(dG).poly(dC) contains adjacent guanine bases,
shows the importance of the ,2-IntraSCL (large increase upon platination
in the flotation density value). Trans-DDP increases the flotation
density of DNA proportionally to its G- content, but it does not increase
it so much for poly(dG).poly(dC), in contrast to cis-DDP, i.e., it is not
showing any selectivity in the formation of IntraSCL, in neighboring bases
[104].
(j_i) The breaking of platinated DNA with enzymes possessing selectivity,
e.g., restriction endonucleases. This selective breaking is inhibited by
cis-DDP when the sites cut by the enzyme, have nearby the sequence, oligo
(dG).oligo(dC) [105-107].
Also in experiments with exonucleases and with the use of techniques for
sequence analysis of DNA, it is seen that the breaking of the platinated
DNA is inhibited in oli9o(dG) sites, most probably due to the formation of
IntraSCL with cis-DDP [106-109].
(iii) NMR spectroscopic techniques on the interactions of di- and oli9o-
nucleotides with cis- and trans-DDP show the formation of IntraSCL.
(i_zv) Binding of the two isomers cis- and trans-DDP with DNA followed by
hydrolysis (mainly enzymatic or other) and identificatio9 of the obtained
products with chromatographic HPLO and FPLO analysis and HNMR, showed for
1
cis-DDP the existence of only 1,2-IntraSCL of the GG and AG but not of the
6A (5’----3’) type [99, 110, 111].
Thus, HNMR and chromatographic methods of the reaction products of
cis-DDP with various homo- and hetero- dinucleotides showed that there is a
kinetic selectivity in the reaction with d(GpG), while the reaction with
d(ApA) was very slow [112].
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In the case of the reaction of ci__s-DDP with d(GpC), a 1-2 complex of the
metal with the ligand is formed, bound only through N of G. Cytosine is
not taking part in the complexation, under the conditions of the reaction,
showin the lack of selectivity for a 1,2-Intra$CL with d(GpC).
Studies on interactions of cis-DDP with the autocomplementary
hexanucleotide d(ApGpepCpCpT) followed by HPL
chromatographic
separation and characterization of the products with 2D- HNMR spectroscopy,
showed the formation of almost exclusively of a 17-membered chelate ring or
an 1,2-IntraSCL between the metal and G(2), 8(3) through N7 [113, 114].
The same hexanucleotide reacting with trans-DDP produces mainly
1,3-IntraSCL, forming a 23-membered chelate ring, involvin the N7 of A(1)
and N7 of G(3) [115] (Fig. 12). o o
H HO .... HoH NH.
H H
HNH O
H
Fi9. 12. Bindin9 of trans-DDP ith the nuc]ootide d(ApGpGpCpCpT)
( Reproduced by permission from tel. Ill5] ).
Trans-DDP on ghe other hand after reacgion ith DNA and enzyme
hydrolysis separation of ghe products ith HPLC and identification of them
with atomic absorption and H ffR spectroscopies, formed intrastrand
cross]inks ith single stranded DNA of the dG-Pt-dG type (aboug 60g), of
the dG-Pt-dA type (about 35g) and dG-Pt-dC (about 5). ith double
stranded NA ghe correspondin9 amounts ere dG-Pt-dG (50), dG-Pt-dA (40g)
and d6-Pt-dC (10). The differences have been attributed to the 9rearer
lability of the single than the double stranded DNA [116].
The difference between cis-BBP and trans-OP seem to be related to their
IntraSeL type that they form wgh DNA. h]e cis-DDP forms a chelate tin9
wgh two successive 9uanine bases (1,2-IntraSCL), trans-DP seem to prefer
a 1,3-IntraSCL ith to non ad3acent 9uanine bases of the type d(pXp)
(X=any nuc]eobase). Boh IntraSCL however, inhibit the synthesis of OA, +
while a monodengate binding, e.9. of [(dien)PtC]] (dien=diethy]ene
triamine) does not [117].
The similar tl2
of the monodentate complexes with A of both isomers,
show that the bioSo91ca] nactivity of trans-DDP cannot be due o the rate
of the formation of a bidentate complex [116]. It can however be related
to the reaction rate of su]fydry] (SH) 9roups with the monodenta]]y bound
to DA trans-DOP, which is faster in comparison ,ith the ones of cis-DDP,
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Further studies with H NMR [119] on the interaction of cis-DOP with the
oligonucleotide d(TCTCGTCTC)d(AACCAA) show chelation with the two
adjacent guanine bases at the center of the one strand. The results also
showed th
Crysta
the react
important
product o
There are
The 9uan
vary from
C3’-endo conformat on.
- _ ..
03 ’B
Fi. 13. Crystal strucuro of the complex !-[(NH)Pt(N/,N/-d(ppG)]
( Reproduced b permission from ref.[12
at the double helix structure was present after platination [119].
structure determinations have also been carried out on some of
ion products of cis- and trans-DDP with ol ilonucleotides. Very
was the elucidation of the crystal structure of the reaction
f cis-DDP with d(pGpG) forming a 1,2-IntraSCL [120,121] (Fig. 13).
four crystallographically independent molecules in the unit cell.
ne planes are in a head to head arrangement and their angle
76.2 to 86.8 in each one of them. The sugars adopt the
This corresponds to the type of bonding that cis-DDP is expected to make
in majority with DNA. It implies a bendin of the double helix axis of DNA
by 32-34 It can not be given b trans-DDP, since the distance between
its two chlorines is 4.64 X, compared to the 3.34 X in cis-DDP, comparable
to the distance of the two adjacent uanine bases in B-DNA [215].
The elucidation of this structure was confirmin previous H NMR studies
on the interactions of cis-DDP with the d(epG) forming 1,2-Intra$CL in
solution [122].
Similar 1,2-Intra$CL was also found in the structure of the complex
ci s- [ (NH3)2Pt(d(GppG)-N (2), NT. (3)) ] [123].
Other crystallographi studies include the structures of cis- and
trans-DDP with t-RNA
pne
from brewer yeast with 6 and 3 resolution,
respectively [124, 125]. Cis-DDP formed 1,2-IntraSCL of the type d(GpG)
and d(ApG) [124], while trans-DDP [125] is monodentally bound at G(34)
[125]. Also in the structure of [(dien)Pt[d(ApGpA)-NT(2)], complexation
takes place only through N7 of G(2) (Fig. 14).
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Fig. 14. Crystalo structure of the complex (dien)Pt[NT(2)-d(ApGpA)],
].5 A resolution ( Reproduced by permission from ref.[23]
with
).
Molecular mechanics calculat
ds oli9onucleotide of B-DNA t
mainly 1,2-IntraSCL with the N
possibilities of the double he
angles of 50 and 60. The a
63.2 and 58.4 correspondingl
ion studies [126] on the ci__s-DDP adduct of
ype d(TCTCGGTCTC).d(GAGACCGAGA) containing
7 of G(5) and G(6) showed that two bending
lix axis in the major groove exist,
ngles of the two complexed bases are
y [127]. The hydrogen bondin between
two complexed guanine bases with their complementary cytosines is
modified. The sugar conformation is changed to C3’-endo from C2’-endo
with
then
the
also
for
the platinated 9uanosines and a hydrogen bonding exist between the ammonia
molecules of cis-DDP and the 5’-phosphate group. Of the two bending models
for the structure of B-DNA in the presence of cis-DDP, the one
o
corresponding to 63.2 is more stable by 19.3 kcal/mol under high ionic
strength conditions (i.e., with maximum neutralization of charge of DNA),
called "model of high salt concentration", while in lower ionic strength
the 58.4 model is more stable, called "model of low salt concentration"
[126].
Similar molecular mechanics calculations for the binding of cis-DDP with
nucleotides of the type XpG and GpX, (X-base), show selectivity for
platination when X=G [128].
The calculated bending angles of the double helix of DNA with molecular
mechanics may however differ considerably from the real values, if factors
like interactions with the solvent etc are not taken into account. For
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the type example, when the part of B-DNA containing 22 base pairs of
(Scheme I), representing 2.5 turns of the helix, is treated
TCTCCTTCTTGGTTCTCTTCTC
AGAGGAAGAACCAAGAGAAGAG
Scheme I
with cis-DDP followed by gel electrophoresis and comparison with a part of
DNA with bending angle of 20, it is found that the bending angles in the o former with 1,2-IntraSCL vary from 35-40 differing considerably from the o ones calculated by molecular mechanics of 50-61 [I9,130].
Combined molecular mechanics and ID- and 2D- H NMR studies, on the
reaction of cis-DDP with the double hel ix type 10-nucleotide
d(GCCGGATCGC).d(GCGATCCGC) showed a bending angle of the helix by 55-62
after the formation of 2-IntraSCL of the metal with G(4) and G(5) and an
unwinding of it by 12-19
$
[131].
Recent studies on the cytotoxicity of the 1,2-IntraSCL if d(GpG) type
caused by cis-DDP on the DNA of E.coli, using as a model the 12-nucleotide
d(TCTAGGCCTTCT) [132], in combination with previous work on the
cytotoxicity of the 1,2-IntraSCL of d(ApG) type [133] show that this latter
type of binding should be about 5 times more toxic than the former one.
This indicates that we have to be cautious in determining the more
cytotoxic IntraSCL of the drug.
During the replication of platinated DNA, the 5-position of the sugar
presents the larger distortion, mainly due to the structural change to the
C3’-endo conformation of the latter. As a consequence mutation may occur
at this position (replacement of C by A) and not at the 3’ where the
smaller (maintenance of the C2’-endo configuration) [132] distortion is
(Fig. 15).
Mutation at the 5’position of guo with C3’-endo sugar
conformation (Reproduced by permission from ref.[1321
Fi9. 15.
A comparison of the effects caused by platination (cis-DDP) and
methylation at the N7 position of dGuo and dGpG, shows that the former
stabilizes more than the latter the N-glycosidic bonding towards acid
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hydrolysis and does not cause the opening of the imidazole ring [134].
This means that the N7 platinated 9uanines are slower hydrolizin9 the
N-91ycosidic bonding than the methylated ones, e.9. slowly apopurinate from
DNA. Also the difference from a nucleoside (dGuo) and a dinucleotide (GpG)
upon platination consists to the easier breaking of the N-glycosidic
bonding in the former and of the Pt-N7 bonding in the latter [134].
It was finally proposed that for the formation of the 1,2-IntraSCL at
the d(GpG) section of DNA, the cis-DDP is initially accidentally bound with
one guanine base monodentally through N7 in a reversible fashion. In this
way, ci__s-DDP may "march" on the double helix until it is able to form a
permanent 1,2-IntraSCL when it "finds" two adjacent guanine bases [135].
(c) In.terstrand Crossl inks (InterSCL) Usual ly the percentage of InterSCL
is less than I; of the amount of cis-DDP bound with DNA, though it seems to
increase with time up to 3% [136] or even up to 5% according to others
[137]. Both isomers cis- and trans-DDP form such bonds in comparable
amounts [106].
It should be noted that the covalent binding of cis-DDP with the DNA
bases creates local unwinding of the double helix, resulting to regions of
single stranded structures within the macromolecule and to a final
shorternin9 of the active length of it [97].
In DNA rich in G,C, it was proposed [138] that the initial formation of
a N706 chelate with cis-DDP of guanine has as a result the breaking of the
hydrogen bondings between the two bases G,C in opposite strands. This was
followed by the formation of interstrand crosslinks between the
deprotonated NI atom of guanine and the N3 of cytosine [138]. This was
however, never confirmed.
The formation of InterSCL between two guanine bases of opposite strands,
bound to Pt(II) through their N7 atoms create an important distortion of
the secondary structure of DNA, as molecular three dimensional models show.
More particularly the two helixes are turned in opposite directions
approaching each other and the distance between the 91ycosidic bonds is
reduced to 10 from 12 X.
It was also proposed that such InterSCL are formed between G-C(5’----)3’)
pairs, though this was not confirmed [139].
When cis-DDP reacts with the oligonucleotide d(CTTCTCCTTGCCTCTCCTTCTTC)
and after isolation and indentification of the products with gel
electrophoresis and molecular models, it was found that the sequence
d(GC/CG) which was platinated was distorted and a bending of 55 was
observed in the direction of the major groove. The average angle of turn
of the bases is kept constant however. This occurs, because for the
0
formation of the InterSCL the two guanine bases should approach to 3.4 A
(bite distance in cis-DDP) from the 7 X, which is their normal distance in
B-DNA [140].
The InterSCL may not play a very important role in the cytotoxicity of
cis- and trans-DDP [141] or of ci__s- and trans-diamino-tetrachloro-platinum
(IV) [142], since it is only formed in a very small percentage, though more
recent results show the opposite [143, 144].
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(d) 1,3-IntraSCL As already mentioned, both cis- and trans-DDP can
1,3-IntraSCL. More details of the 1,3-IntraSCL formed by cis-
rans-DDP are given here.
H NMR studies on the interaction of the trinucleotide d(GpCpG)
trans-DDP showed complete unstacking of the bases, while the sugar of
changes conformation from C2’-endo to C3’-endo[145]. This is similar
the change caused to the sugar at the 5’-position, in the 1,2-IntraSCL
ci__s-DDP with d(Gp6), but differs from the 1,3-IntraSCL of cis-DDP with
d(GpCpG) [146] favoring the C2’-endo conformation. This may be related
the lack of antitumor properties of trans-DDP.
form
nd
with
G(1)
to
of
to
Also the reaction of trans-DDP with the oligonucleotide d(CCTCGAGTCTCC)
(12-bases) gave products that were characterized after enzymatic digestion
and HPLC chromatographic separation, by H NMR spectrosopy [147]. The
I
reaction had taken place at pH=3, so that complexation at NI of A(6)
(pK=3.8) was avoided and resulted in the formation of the 1,3-IntraSCL
[147]. Monodentate intermediates of trans-DDP through the N7 of G(5) or
(7) can be detected.
When the double stranded 12-nucleotide d(CCTCGAGTGTCTCC).d(GGAGACTCGAGG)
is used instead, it is seen from the molecular models of the free and
platinated nucleotide (Fig. 16) that because of the 1,3-1ntraSCL, the A(6)
at the middle is not anymore stacked with the complexed guanine bases
Ca)
(b)
Fig. 16. Molecular models of (a) free and (b) bound with trans-DDP,
polynucleotide d(CCTCGAGTTCTCC).d(GGAGCTCAGAGG) (Reproduced by
permission from ref.[147] ).
surrounding it and its sugar takes the C3’-endo conformation [14]. The
difference from cis-DDP [127] is due to the fact that this causes a
considerable bending of the double helix in the main groove of B-DNA, by
400-70 because of the 1,2-IntraSCL, while the trans-DDP bending angle is
only 185, because of the 1,3-IntraSCL.
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The rate constant of the formation of t_h 1_,-Intra$CL, with the
nucleotide of trans-DDP was, k:(12.5+0.4) _
10_ISeC while with DNA had
comparable value of k=(9.6+0.4) X 10 sec [115], as measured with
Pt NMR spectroscopy.
-5 -1
Atomic absorption spectroscopy 9ave the value k=(5.4+_0.4) XlO sec
[115], for the rate constant of the reaction of DNA with trans-DDP [148],
while it is reminded that the rate constant for the replaemen of the
first chlorine by a water molecule (Fig. 6) was k.’=1.9 X 10 sec This
l
indicates that trans-DDP binds to DNA in two pseudofirst order steps, the
first being the chlorine replacement and the formation of a monodentate
complex with the N7 of guanine and the second, which is faster, the
formation of the 17-membered chelate through the N7 atoms of e(5) and
of the nucleotide [148]. The rate of the total reaction seems to be
determined from the replacement of chlorine by water.
The formation of a bidentate complex by the two isomers was considered
until today as non reversible.
the reaction o.f the 12-nucleot
pH and after enzyric hydroly
HPLC and H and Pt NMR spe
G{6) and G(8) was formed in
1,4-IntraSCL between the N3 of
solutions [149]. The equilibr
was found to be 3, with prefe
half life tim. of the 1,3-Int
62C, with AH-91_+2 kj/mol and
In conclusion, the 1,3-Int
t rans-DDP does not seem to be
Recently however, it was found that during
ide 5’-d(TCTACGCGTTCT) with trans-DDP at low
sis of the products and characterization with
ctroscopy, a 1,3-!ntraSOL between the N7 of
itially, followed by a rearrangement of a
C(5) and the N7 of G(8), in neutral aqueous
ium constant of this rearrangement reaction
The
at
fence to the formation of 1,3-IntraSOL.
raSL was 1.29 hrs at 30C and 3.6 hrs
AS =-58+8 J/mol K [149].
raSCL type bonding formed by both cis-
responsible for the antitumor action of
former, although it partially inhibits the DNA synthesis. Also,
formation of the IntraSCL should not be considered as non reversible,
in the case of the
importance of the
investigatioon [149].
and
the
the
like
1,3---1,4 rearrangement, although the biological
latter is not as yet understood and is under
(e) Bidentate binding of cis-DDP with one base of DNA The formation of a
N706 chelate of Pt(II) with the same base of guanine was proposed in the
past, both with DNA [138, 150] and with simple 9uanosine [48] based on
spectroscopic data and chemical reactions.
Similar chelates with Pd(II) were also proposed [151-153].
The importance of the possible formation of such a chelate by cis-DDP is
immediately obvious, since trans-DDP is unable to form
explain the antitumor properties of the former and the
latter.
Various oopurines can form such
complex [(n -Cp)o(Theoph)Ti] [154],
through N706 wit Ti(!V). Similar
complexes [(n -CP)2Ti]3 (Han)]c]’
it. This might
inactivity of the
N706 chelates. For example, in the
theophylline is bound bidentally
chelates were also found in the
(Xan-Xanth ne) 155 and
173Vol. 2, No. 3, 1995 On theMechanism ofAction ofthe AntitumorDrug cis-Platin (cis-DDP)
and Its Second Generation Derivatives
(8-MeS-Theoph)sCU
(py)
2 J, (8-MeS-Theoph=8-methyl thi o-theophyl ne) [1561.
contains The hexameric ructure of the complex [(CH3)^Pt-(theoph-2HCl)3
also such el ates 157] Also, when the comp met, i trans-[(dien)Ptequivalens(OH)2(N7-9-MeGDcl, ](Cl04)2r’-2H-Omeis
left for one day a+
with 2 of the (u ien) Pt (OH) Cl (9-MeGH-NT) is
5H
obtained. In t e H NMR, it is
2 (8)
8.37 ppm. After 12 more days new
products with u =
8.50 and 5 u =
8.54 ppm are observed, which may be
due eii:her to NTlhelates or NI’,’( bridged complexes [158].
Cytosine, a pyrimidine base, can also form a four membered chelate ring
between the N3 atom of the ring and the exocyclic amino group at 4 [159].
Macrocycle chelates may also be formed bween
the N7 of 9uo and the
phosphate group and cis-DDP in DNA as P NMR studies showed. The
phosphorous signal is shifted downfield by 1.4 ppm and this is not observed
with trans-DDP 160]. This result was also more recently
interpreted as due to a particular conformation of the oligonucleotides
called hairpin-like [161, 162].
Indications for the formation of such bonds have also been 91ven for the
reaction of cis-DDP with GMP, with fast atom bombardement mass
spectroscopic techniques, on the products of the reaction of 1:1
stoichiometry [163].
In conclusion, the N706 chelate of guanine or any other oxopurine with
cis-DDP has never been found yet in any crystal structure solved with
X-rays, that unequivocally would prove its existence. Therefore the
formation of such a chelate in vivo seems unlikely [164].
.(f) Interactions of cis- and trans-DDP with p.roteins and formation of DNA
-Pt-protein crosslinks Cis-DDP reacts with plasma proteins and about 50%
of the drug is bound there one hour after administration [24]. The main
binding site of the drug is the sulfur of 91utathione [165-167] or the
sulfydryl group of cysteine. This binding was correlated with the higher
nephrotoxicity of the drug compared to Iproplatin and Paraplatin [167].
Due to the high trans-influence of PIII), ammonia liberation is observed
in such reactions in the plasma, by N NMR spectroscopy [72]. Trans-DDP
is bound to a larger extent than cis-DDP by histone proteins [168], while
cis-DDP reacts faster with non-histone proteins [169].
Both cis- and trans-DDP are bound to chromatine forming DNA-Pt-protein
crosslinks or IntraSCL of proteins [170-172]. Trans-DDP reacts mainly with
the S atoms of Cys, Meth, or with the nonprotonated His, at physiological
pH 173-175].
More specifically, it was proposed that cis-DDP is forming selectively
crosslinks between the low molecular weight and high mobility group
proteins HMG1 and HMG2 and DNA and that the bonding with the latter takes
place on the main groove, while the proteins retain an e-helix structure
[175].
Cross]ink bonds are also foraed by both isomers wit.h non-histone
prot.eins of HeLa ce]]s, t.hough l:rans-DDP t.o a larger exl;ent,. Both isomers
bind 1;o a larger proport.ion t,han in hist,one prot.eins due t.o the 9reat,er
174K Aletras, D. Hadjiliadis and N. Hadjiliadis Metal BasedDrugs
methionine content of the latter [176, 177]. Such crosslinks have been
correlated with the antitumor or cytooxic action of he drug [178-180].
Since heir percentage is small however, this seems unlikely today [95].
Also, the DNA-Pt,-proein cross]inks for cis-DDP are more resisan o
repairing enzymes than those for trans-DDP [181]. Furthermore, the
formation of more DNA-Pt-g]uahione cross]inks of cis-DDP than of
trans-DDP, was explained wih the lower toxicity of the drug, since in his
way it forms a smaller number of 1,3-[ntraSCL with DNA [182].
Due to the easier formation of DNA-P-protein cross]inks by trans-DDP,
the latter was used o map regions of t-RNA in he vicinit,aith,, a protein.
For example, such a cross]ink is formed between the t-RNA of the yeast
of Saccharomyces cereviase (G) and of the protein aminoacy]o-t-RNA-nva]-
-synthetase [183]. The sites of the cross]inks of trans-DDP are the ones
of t-RNAva
that strongly interac with the protein and in this way they
are determined [183].
Proteins play an important role in he formation ot’ a "complex" with
DNA, once the IntraSCL ot 1,2-type wih cis-DDP are formed. For example,
it is known that the tripeptide LysTrpLys form a stacking complex only with
DNA treated with cis-DDP but not with trans-DDP. This was attributed to
the formation of certain parts with primary structure in the macromolecule
[184].
In 1990 L ippard e a] [185] discovered a group of proteins, named DNA
Damage Recognition Proteins-DRP’s. These "recognize" i.e., form selective
complexes only with the 1,2-d(GpG) and d(ApG) IntraSCL of cis-DDP wih DNA
and not with the 1,3-IntraSCL. They are also unable to recognize the
corresponding 1,3-IntraSCL of rans-DDP [185]$
The action of these proteins (NW=IXIO) as correlated with the
unwinding of he DNA double helix, which in the case of 1,2-IntraSCL is
0 o
13 while in he case of he 1,3-IntraSCL wih cis-DDP is 23 also o the
bending of the helix axis in the 1,2-IntraSCL, being 35 [186].
Extensive work was done afterwards for determination of the structure of
these proteins. :r was found [187-190] that hey be]on9 o he group of
he non-hisone proteins and ca]led High Nobility Group, HNG1,2. HNG1 and
HNG2 consist of 214 and 209 aminoacids respectively with N-terminal
aminoacid 9]ycine and differ in 43 positions (about 20), e.g. in 6, 33,
38, 56, 65, 71 etc. They are consisting of hree parts; one very acidic
(C-terminal par) involving a]mos exclusively aspartic and 9]uamic acids,
while the wo others are consisen of wo homogenic parts of 80 aminoacids
each.
The proteins have a spheric structure with a positively charged nucleus
able to "bind" with DNA, through its negative charges, with electrostatic
interactions [187]. They have the ability (i) to bind strongly with the
primary rather than the secondary structure of DNA [191, 192], (ii) to
destabilize or to unwind the DNA double helix [193], (iii) to promote
superhelix formation of plasmids and (.i_yv) to replace histone proteins when
they "bind" with DNA [187].Vol. 2, No. 3, 1995
It was further proposed [187,
crossed in a "X" shape, which
type, They are formed during
[187-189].
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189] that they are forming two -helixes
selectively also recognize DNA of crossed
the superhelix formation of natural DNA
It is believed that the 1,2-1ntraSCL of cis-DDP are protected by these
proteins and in this way are not "recognized" by cell enzymes leading to
the final death of the cell. This theory is under extensive investigation
[190]. To this behavior of the proteins, the negative charge of their
terminal carboxylate groups, at physiological pH, may play an important
role in the ability to form hydrogen bonds [187-189].
The 26 first aminoacids of two such proteins have been coded, with MW
25.6 and 28 kiloDaltons and correspond to HM-I and HMG-2, respectively
[194].
4. ELEMENTS OF PHARMOKOKINETICS OF cis-DDP PARAPLATIN AND IPROPLATIN.
Cis-DDP and carboplatin are administered intravenously in maximum doses
of I00 and 400 mg/m2 respectively, every 4 weeks. The first is
administered in a freshly prepared solution in distilled water with
mannitol in 1-I stoichiometry. Paraplatin is diluted with a 5% dextrose
solution in water or with a 0.9 NaCl or with distilled water. After 3 hrs
from the administration of cis-DDP, about 90% of the drug is bound with the
plasma proteins, while in hr, 50% of it is bound [195]. Paraplatin on
the other hand is bound 50% only after about 6 hrs (Table I).
Table I. Comparison of pharmakokinetics of cis-DDP and Paraplatin
Half Life
Free Pt, non bound to proteins
Precursor compound
Urine Excretion
24 hrs
3 days
5-6 days
Parapl at n Ci s-DDP
6 hrs lhr
1.5 hrs 0.3-0.5 hrs
70% 30%
8O%
40-50%
In conclusion, in the case of cis-DDP a prohydration of the patient is
needed and the intravenous administration is slow (solubility I mg/mol in
0.9% NaCl solution), requirino often admission of the patient in hospital
and consequently, increasing the cost. Toxicity, nausea and vomiting
tendency appear and are treated with the administration of high doses of
antiemetic agents. On the contrary, with Paraplatin there is no need of
prohydration. Owed to higher solubility, the administration is fast and
the patient is not staying in hospital. Most important, its toxicity is
smaller, with myelosuppression the dose limiting toxicity, while nausea and
vomiting are treated with lower doses of antiemetics.
Therefore paraplatin or carboplatin shows comparative advantages than
cis-DDP having lower toxicity, thus allowing increase in dose up to 400
m9r/m2 and lower cost of therapy. Also, its aqueous solutions (0.9 NaCl)
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are stable for a long time and they should not be freshly prepared before
use, like cis-DDP.
The mechanisms, of action of cis-DDP and carboplatin are similar, i.e.,
carboplatin like cis-DDP react with DNA and form InterSCL and IntraSCL, as
well as lntraSCL of DNA-Pt-protein type [196]. In aqueous solutions, the
1,1-cyclobutane dicarboxylic anion is liberated in two steps, with breaking
first of one Pt-O bonding and simoultaneous nucleoph]lic addition of water
41 c I owe  (or of other ligands, in vivo) wit+k1:8.0X10- sec- a 2 1
by
its complete release with k^=k[ and k=1.BIX10- dm mol s (acid
catalyzed). The inverse reactions (formation of the chelate) s not taking
place in the presence of acid [197].
The rate constant 7fo the overall hydrolysis of carboplatin was
0 estimated to be 7.2XI0 s in phosphate buffer solution of pH-7 at 37 .
As exposed, it seems that the reaction of carboplatin with DNA proceeds in
two steps, i.e., formation of a monodentate complex first and a bidentate
afterwards. Based on the hydrolysis constants, the quantity of carboplatin
required to achieve the same percentage of binding with DNA, as cis-DDP,
was calculated to b aout
100 times larger than the latter (under similar
conditions, k-8X10- s- ), although in vivo a 20-40 fold excess seems to be
enoulh [198].
In summary carboplatin, (i) is about 45 times less toxic than cis-DDP,
(i__i) the IntraSCL that it forms with DNA appear 12 hours later than those
of cis-DDP and (iii) the IntraSCL DNA-proteins that it forms show their
maximum quantity 6 hours later than the corresponding ones with cis-DDP
[ ]. 19"H NMR studies show that cyclobutane is rotating fast around the
carboxylate groups, bonded to Pt(11), in carboplatin [200]. lt6wa also
shown [201] that carboplatin reacts faster with 5’-GMP (k=4.1X10- s- ) than
the phosphates (k=4,alO-Ts-1) and chloride (k=1,210
-6 -1 s ) or water (k<5.9
X lO-Us ). Once the 1-1 complex of the metal ligand is formed, the
formation of the 2 complex through N7 is fast (k=1.3X10
-5 "1
Iproplatin (CHIP) on the other hand containing Pt(IV), acts as a
prodrug, to produce the corresponding complex with Pt(11), which then
reacts with DNA. This is seen from the fact that for its reaction with DNA
in vitro, the addition of a reducing agent like Fe(ClO4)^.6H20 or ascorbic
acid is required [202]. The ra!e onstant of the reaction of iproplatin
with ascorbic acid is k 0.584 M-"s- at 37C... (t.I/2.=I.5 hrs [20}.]. For its
reaction with 5’-MP at 37C and 1:1 stocn]omery, k<1Odm mol- h
-I
(quite
slow) and t />10 hrs and consequently its action requires prior reduction
Pt(ll). IZthe reaction of 3its ] ]’Pt(l) analog with GMP however, have to
k =I.69 at125C and k-2.96 dm mol- s- at 370 (for cis-DDP 1.44 BRd 2.82
 o 0 ex,
(for c_is_-DDP 0.238 and 0.50 dm tool s [204 1205], i.e., both are faster reactions.
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5. CONCLUDING REMARKS.
On the Mechanism ofAction ofthe AntitumorDrug cis-Platin (eis-DDP)
and Its Second Generation Derivatives
Despite the great deal of work performed on the subject, there is no
definitive conclusion concerning the mechanism of action of cis-DDP, since
there are still unanswered questions e.g., the non recognition of the
1,2-1ntraSCL by cell repairing mechanisms, while they are related with DNA
replication. It can however be argued that the 1,2-IntraSCL may consitute
the main damage caused by cis-DDP to DNA, thereby leading to antitumor
action.
The ability of cis-DDP to form 1,2-IntraSCL with d(ApG) and d(GpG) and
the inability of trans-DDP to act similarly and form only 1,3-IntFaSCL with
d(GpXpG) as well as InterSCL, may also be the main difference of the two
isomers, leading to antitumor action for the former and to toxicity only
for the latter. Cis-DDP causes a greater distortion to the secondary
structure of DNA, while trans-DDP causes a greater local distortion, i.e.,
near the platination site.
The conformation of the sugar at 5’ may also play an important role in
the mutagenic and toxic dose of the drug during the formation of the
I, 2- I r’Ft raSCL.
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